Skip Navigation
Skip to contents

JLC : Journal of Liver Cancer



Page Path
HOME > J Liver Cancer > Volume 11(1); 2011 > Article
Review Article Systemic Therapy in Advanced Hepatocellular Carcinoma
Hye Jin Choi
Journal of Liver Cancer 2011;11(1):33-39
Published online: February 28, 2011
Division of Oncology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea
Corresponding author:  Hye Jin Choi,
  • 1 Download
  • 0 Crossref
  • 0 Scopus

Understanding the mechanism of hepatocarcinogenesis has provided the opportunity to evaluate the efficacy of molecularly targeted agents in HCC. Sorafenib is a multikinase inhibitor with antiangiogenic, proapoptotic, and Raf kinase inhibitory effects, and it is the first new agent to consistently prolong overall survival in patients with advanced hepatocellular carcinoma (HCC). The success of sorafenib is a milestone for systemic therapy of HCC, shifting the paradigm of systemic treatment to molecular targeted agents. Many novel agents that inhibit angiogenesis, epidermal growth factor receptor, and mammalian target of rapamycin are under clinical development. This review attempts to summarize the current status and future perspectives of systemic therapy in HCC.

JLC : Journal of Liver Cancer